Immunobiota Therapeutics advanced its oral immune tolerance strategy for type 1 diabetes with IBT-100, a non-immunosuppressive metabolite-based therapy designed to deliver disease modification without the burden of antibody approaches. The company said the candidate is moving toward Phase Ib/IIa testing as it targets immune-pathway reset rather than incremental glucose control. The program’s emphasis is on shifting the therapeutic model away from injectable immune modulation toward a gut-targeted, oral intervention intended to reduce hospital exposure and avoid generalized immune suppression. The approach is being developed in a landscape where disease modification remains elusive and safety constraints often limit immunology interventions. For the broader industry, Immunobiota’s move highlights continued interest in oral immunomodulation and microbiome-adjacent drug mechanisms, particularly in areas where long-term treatment risk profiles can limit adoption. Next milestones will center on early safety/tolerability signals and clinical biomarker readouts that indicate immune engagement consistent with tolerance induction.